Download Metastatic colorectal cancer

P er son alized Onc ol ogy Sol uti ons
Experience real-world results, one case at a time
Metastatic colorectal cancer
Personalized TumorGraft™ case study: 44-year-old female diagnosed with metastatic
colorectal cancer who had 3 prior regimens1
First line: FOLFOX (5-Fluorouracil, Leucovorin, Oxaliplatin) plus Bevacizumab (Avastin);
Second line: FOLFORI (5-Fluorouracil, Leucovorin, Irinotecan);
Third line: Cetuximab monotherapy
PERSONALIZED TUMORGRAFT™ RESPONSE TO DRUG TESTING
First round of drug testing (fourth line of treatment)
1200
Control
Irinotecan 100mg/kg; q7dx3
1000
3
Tumor Volume (mm )
800
600
400
200
0
0
4
6
8
11 13 15 18
20 22 25 28 32 35
39 42 46 47 49 53 56
Time (Days)
1. Patient’s pelvic tumor regressed by 60% following Irinotecan monotherapy (partial response)
• The patient had resolution of the hydronephrosis
• Patient remained in partial response for >50 months
2. Additional drug testing revealed that maximal response in the patient’s Personalized TumorGraft™
was achieved with Laptinib combined with Xeloda (fifth line of treatment)
• Patient’s tumor regressed (partial response) for 6 more months
1
Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, et al. A Pilot Clinical Study of Treatment
Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther June 2011.
RESPONSE TO FOURTH-LINE TREATMENT
Before Irinotecan Treatment
After Irinotecan Treatment
Pelvic
Metastases
Resolution of
Hydronephrosis
Further investigations: second response to Irinotecan therapy
500
IRINOTECAN
• In an effort to understand why the patient had
a second response to Irinotecan, Champions’
scientist compared her levels of Irinotecan
and its active metabolite SN-38 to other
Personalized TumorGrafts™
450
400
6000
350
SN-38 (ng/gm)
IRINOTECAN (ng/gm)
5000
4000
3000
2000
300
250
• The patient’s Personalized TumorGraft™
activated Irinotecan to its active metabolite
SN-38 more readily than those of other patients
200
150
100
1000
50
0
0
CRC005
CBI0805
CRC005
CBI0805
Case study conclusion
• The Personalized TumorGraft™ revealed that the patient would respond best to one of the three combined treatments
she received previously
• Patient responded to two courses of Champions-guided treatment
• The patient would have likely never received Irinotecan again if not for Personalized TumorGraft™ testing
Personalized Oncology Solutions
Champions Oncology, Inc.
One University Plaza, Suite 307
Hackensack, NJ 07604
Phone: 201.808.8400
www.ChampionsOncology.com
© Champions Oncology 2011